Radiation Oncology Journal

  • 제31권3호
  • /
  • Pages.171-174
  • /
  • 2013
  • /
  • 2234-1900(pISSN)
  • /
  • 2234-3156(eISSN)
대한방사선종양학회 (The Korean Society for Radiation Oncology)
권호 표지
DOI QR코드

DOI QR Code

Sorafenib-triggered radiation recall dermatitis with a disseminated exanthematous reaction

  • Oh, Dongryul (Department of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine) ;
  • Park, Hee Chul (Department of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine) ;
  • Lim, Ho Yeong (Division of Hematology and Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine) ;
  • Yoo, Byung Chul (Department of Internal Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine)
  • 투고 : 2013.08.13
  • 심사 : 2013.09.11
  • 발행 : 2013.09.30
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Sorafenib is a multi-targeted kinase inhibitor, which is the current standard treatment for advanced hepatocellular carcinoma (HCC). Only one case of radiation recall dermatitis (RRD) associated with sorafenib has been reported so far. Our patient with recurrent HCC was treated with palliative radiotherapy (RT) for the chest wall mass. Sorafenib at 400 mg twice daily was begun on the day following RT. On the 14th day post-RT, an erythematous patch was observed on right chest wall which matched area previously irradiated. It was consistent with RRD. Ten days later, a disseminated exanthematous rash and severe pruritus occurred. Sorafenib was stopped and an oral antihistamine was prescribed to relieve symptoms. At the 1-week follow-up after the cessation of sorafenib, all symptoms were resolved. Physicians should be alert to this recall phenomenon as it can occur both in the skin and elsewhere and the occurrence of RRD may be unpredictable.

키워드

참고문헌

  1. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378-90. https://doi.org/10.1056/NEJMoa0708857
  2. Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, doubleblind, placebo-controlled trial. Lancet Oncol 2009;10:25-34. https://doi.org/10.1016/S1470-2045(08)70285-7
  3. Robert C, Mateus C, Spatz A, Wechsler J, Escudier B. Dermatologic symptoms associated with the multikinase inhibitor sorafenib. J Am Acad Dermatol 2009;60:299-305. https://doi.org/10.1016/j.jaad.2008.06.034
  4. Camidge R, Price A. Characterizing the phenomenon of radiation recall dermatitis. Radiother Oncol 2001;59:237-45. https://doi.org/10.1016/S0167-8140(01)00328-0
  5. Chung C, Dawson LA, Joshua AM, Brade AM. Radiation recall dermatitis triggered by multi-targeted tyrosine kinase inhibitors: sunitinib and sorafenib. Anticancer Drugs 2010;21:206-9. https://doi.org/10.1097/CAD.0b013e328333d679
  6. Hymes SR, Strom EA, Fife C. Radiation dermatitis: clinical presentation, pathophysiology, and treatment 2006. J Am Acad Dermatol 2006;54:28-46. https://doi.org/10.1016/j.jaad.2005.08.054
  7. Yang CH, Lin WC, Chuang CK, et al. Hand-foot skin reaction in patients treated with sorafenib: a clinicopathological study of cutaneous manifestations due to multitargeted kinase inhibitor therapy. Br J Dermatol 2008;158:592-6.
  8. D'Angio GJ, Farber S, Maddock CL. Potentiation of X-ray effects by actinomycin D. Radiology 1959;73:175-7.
  9. Hird AE, Wilson J, Symons S, Sinclair E, Davis M, Chow E. Radiation recall dermatitis: case report and review of the literature. Curr Oncol 2008;15:53-62. https://doi.org/10.3747/co.2008.201
  10. Law AB, Junor EJ. Chemotherapy-induced recall of cetuximab and radiation skin reaction. Clin Oncol (R Coll Radiol) 2009;21:77-8. https://doi.org/10.1016/j.clon.2008.11.001
  11. Chung C, Stuart D, Keyes M. Radiation recall reaction induced by adjuvant trastuzumab (herceptin). Case Report Med 2009;2009:307894.
  12. Shrimali RK, McPhail NJ, Correa PD, Fraser J, Rizwanullah M. Trastuzumab-induced radiation recall dermatitis: first reported case. Clin Oncol (R Coll Radiol) 2009;21:634-5. https://doi.org/10.1016/j.clon.2009.03.003
  13. Bostrom A, Sjolin-Forsberg G, Wilking N, Bergh J. Radiation recall: another call with tamoxifen. Acta Oncol 1999;38:955-9. https://doi.org/10.1080/028418699432653
  14. Azria D, Magne N, Zouhair A, et al. Radiation recall: a well recognized but neglected phenomenon. Cancer Treat Rev 2005;31:555-70. https://doi.org/10.1016/j.ctrv.2005.07.008

피인용 문헌

  1. Sorafenib : Radiation recall dermatitis and disseminated exanthematous rash: case report vol.1478, pp.1, 2013, https://doi.org/10.1007/s40278-013-7243-z
  2. Recall radiation dermatitis by sorafenib following stereotactic body radiation therapy vol.7, pp.None, 2013, https://doi.org/10.2147/ott.s64706
  3. Radiation recall dermatitis induced by sorafenib : A case study and review of the literature vol.192, pp.5, 2016, https://doi.org/10.1007/s00066-016-0950-7
  4. Nodular-cystic eruption in course of sorafenib administration for hepatocarcinoma: An unconventional skin reaction requiring unconventional treatment vol.30, pp.3, 2017, https://doi.org/10.1177/0394632017727618
  5. Radiation recall dermatitis triggered by sorafenib after radiation therapy for hepatocellular carcinoma vol.35, pp.3, 2013, https://doi.org/10.3857/roj.2017.00339
  6. Reacciones cutáneas a fármacos en el paciente con leucemia/linfoma vol.32, pp.9, 2013, https://doi.org/10.1016/j.piel.2017.01.010
  7. Radiation Recall Dermatitis in Patients Treated with Sorafenib vol.2018, pp.None, 2013, https://doi.org/10.1155/2018/2171062
  8. Hematuria induced by combination regorafenib and hyperthermia - a radiation recall effect vol.36, pp.1, 2013, https://doi.org/10.1080/02656736.2019.1687941
  9. Spine stereotactic radiosurgery for metastatic thyroid cancer: a single-institution experience vol.32, pp.6, 2020, https://doi.org/10.3171/2019.12.spine191269
  10. Spine stereotactic radiosurgery for metastatic thyroid cancer: a single-institution experience vol.32, pp.6, 2020, https://doi.org/10.3171/2019.12.spine191269